

Merging Basic Science and Population Science to Elucidate Mechanisms of Breast Cancer Development:

The Women's Environment, Cancer and Radiation
Epidemiology (WECARE) Study

Jonine Bernstein, Ph.D.

Overview

- **Context for the WECARE Study**
- **WECARE Study Design**
- **Study Organization**
- **Current Funding and WECARE II Planned**
- **“Lessons Learned”**

The Epidemiology of Second Primary Breast Cancer

- Rare cancer -- 5-10% of women with breast cancer develop a second primary in the contralateral breast
- Breast cancer patients are 2-5 times more likely to develop another breast cancer than are women without breast cancer to develop a first breast cancer
- Risk of second primary breast cancer remains elevated for 30 years after first primary

Risk Factors for Second Primary Breast Cancer

Factor	RR
Early age of primary breast cancer	1.9-2.5
First Primary Lobular Histology	1.8-2.4
Family History of Breast Cancer	1.5-3.0
Mutation carriers	
<i>BRCA1/2,</i>	3.0-5.0
<i>CHEK2, ATM, p53</i>	??

Treatment and Risk of Second Primary Breast Cancer


Factor	RR
Tamoxifen	<1.0
Chemotherapy	<1.0
Radiation treatment	> 1.0

Scatter dose from RT can be substantial 1.0-7.1 Gy. Excess risk range ~5.5-10.7 cases/104 woman-years/Gy.

Ataxia-Telangiectasia

- Autosomal recessive disorder
- Incidence ~1/100,000 live births
- Characterized by progressive neuronal degeneration, immunologic deficiency, radiosensitivity, premature aging/death, and increased risk of cancers
- A-T patients have mutations in both copies of the ATM gene and lack the ability to produce functioning ATM protein -- truncating mutations

Role of ATM in Cellular DNA Damage Response



ATM Heterozygosity and Breast Cancer: Few Studies, Mixed Results

Study	RR
Family Studies (Obligate +/-)	1.0-6.0
Missense Mutations	1.0-15.7
Truncating Mutations	0.5-1.0
 Radiation and ATM	 1.0-5.8

WECARE Study Design

Design

Population-based, case-control study

- Cases are women with bilateral breast cancer
- Controls are women with unilateral breast cancer

Hypothesis

Women who are carriers of a mutation in the ATM gene are more susceptible to radiation-induced breast cancer than are non-carriers.

(Bernstein, ... , Thompson, *Br Ca Res* 2004)

WECARE Study Design

Premise

Restrict study sample to women with first primary breast cancer and study determinants of second breast cancer

- Power to detect main effects (of relatively rare genetic mutations) and interactions with environmental factors enhanced

(Begg...*JNCI*/1996)

WECARE Study Design

Considerations

To examine ATM gene-radiation interaction hypothesis:

- Rare cancer, large sample size required
- Gene large and complex, mutations rare
- Radiation exposure difficult to measure

Required Expertise: Epi, Molecular Genetics, Radiation Dosimetry/biology, and Statistical Genetics and Methodology

WECARE Study Design

Cases (n=713)

- Diagnosed since 1/1/1985 with incident breast cancer
- Diagnosed since 1/1/1986 with contralateral breast cancer
- One year or longer time lag between primaries
- Under age 55 at diagnosis of the first primary
- No other cancer diagnosis
- Alive

WE CARE Study Design

Controls (n=1397)

- With unilateral breast cancer
- Individually matched 2:1 to cases on:
 - Registry
 - Age (5 year)
 - Diagnosis date of breast cancer (4 year)
 - Race
- No other cancer diagnosis
- Counter-matched on radiotherapy status
 - 2:1 (RRT+: RRT -)


WE CARE Study Data Collection

- Women identified through 5 population-based cancer registries (US and Denmark)
- Telephone interview using a structured questionnaire
- During home visits, a blood sample drawn by a study phlebotomist
 - Blood sent to: labs ATM gene analysis; biorepository at MSSM; and Coriell for cryopreservation

Medical Treatment Information and Data for Radiation Dosimetry

- **Sources**
 - Treatment and tumor characteristics information collected registry records
 - Hospital charts
 - Pathology/surgery reports
 - Doctor office /mammography records
 - Radiation oncology files
- **Missing Data**
 - ~ 7% patient records inadequate for dosimetry
 - ~ 2% participants have all documentation missing

Contralateral Breast Dose (cGy): Mean and Range among Patients Treated with Breast Irradiation (1488 patients)



Treated Breast: Tumor Dose

Contralateral Breast

ATM Gene Screening

- **ATM Gene Analyses**
 - Conducted in 4 labs for all 2100 WECARE Study participants (US and Norway)
 - Staged approach: DHPLC followed by direct sequencing
 - All conditions, primers standardized across labs
 - Inter- and Intra-lab QC implemented

(Bernstein, ... , Concannon, *Hum Mut* 2003)

PRELIMINARY RESULTS

Risk of Developing Second Primary by Age at Diagnosis and Time Since First Primary

Age ¹	Time ²	<u>#Cases</u>		RR ³	95%CI
		RT+	RT-		
<45	0-4	90	85	1.1	0.8 - 1.5
<45	5+	72	64	1.4	1.0 - 2.2
45+	0-4	109	120	0.9	0.7 - 1.2
45+	5+	75	93	1.1	0.8 - 1.6

¹Age at diagnosis of the first primary;

²Time since first primary breast cancer;

³Adjusted for exact age at first primary, age at menarche, nulliparity, family history of br ca, chemo

Distribution (%) of 713 Cases by At-Risk Period and Age

Risk Period	Age at 1 st primary				Total
	<40	40-44	45-49	50-54	
0-4	11	14	16	16	57
5-9	8	7	10	9	34
10+	1	3	3	2	9
Total	20	24	29	27	100


Risk of Developing Second Primary Breast Cancer by Radiation Exposure among Carriers of Deleterious ATM Mutations

ATM Carrier Status	<u>Cases</u>		Rate Ratio*	95% CI
	RT+	RT-		
WT	129	142	1.0	0.7 - 1.3
Possible	30	28	1.2	0.7 - 2.0
Likely	22	12	3.6	1.3 - 6.8

*Adjusted for exact age at first primary, age at menarche, nulliparity, family history of br ca, chemo

WE CARE Study Organization

WE CARE Study Working Groups: Field Organization



WE CARE Study Working Subcommittees



WE CARE Study Collaborative Group

Coordinating Center

Jonine Bernstein MSKCC
Xiaolin Liang MSKCC
Abigail Wolitzer MSKCC

Data Collection

Leslie Bernstein USC
Laura Donnelly USC
Valerie Zayas USC
Kathy Lane USC
Jane Sullivan-Halley USC
Jorgen Olsen DCS
Lene Mellemkjaer DCS
Helle Clement Petersen DCS
Lisbeth Bertelsen DCS
Michael Andersson DCS
Kathleen Malone FHCRC
Noemi Epstein FHCRC
Heather Jurado FHCRC
Hoda Anton-Culver UCI
Joan Largent UCI
Kay Bergdahl UCI
Chuck Lynch Iowa
Jeanne DeWall
Lori Odle Iowa

Methods

Duncan Thomas USC
W. Douglas Thompson USM
Bryan Langholz USC
Xinbo Zhang USC
Yaping Wang USC
Colin Begg MSKCC
Marinela Capanu MSKCC
Amanda Hummer MSKCC

Laboratory

Pat Concannon BRI
Sharon Teraoka BRI
Eric Olson BRI
Robert Haile USC
Anh Diep USC
Yong Liu USC
Nianmin Zhou USC
Shanyan Xue USC
Andre Hernandez USC
Evgenia Ter-Karapetova USC
Anne-Lise Borresen-Dale NRH
Laila Jasen NRH
Daug Rodningen NRH
Ake Borg Lund
Therese Sandberg Lund
Lina Johansson Lund
Barry Rosenstein MSSM
David Atencio MSSM
Per Guldberg DCS

Radiation Dosimetry

Marilyn Stovall MDAAC
Susan Smith MDACC
Roy Shore NYU

Repository

Jeanne Beck Coriell
Rick Martinas Coriell
Anh Diep USC
Yong Liu USC
Irene Orlow MSKCC

Consultants

Richard Gatti UCLA
Elaine Ostrander FHCRC
John Boice, Jr. VU

External Advisors

Alice Whittemore Stanford
Jack Schull UTH
Bruce Ponder Cambridge

Program Officer

Daniela Seminara NCI

Other On-Going WECARE Studies

2001-2007	Interaction of Radiation, BRCA 1/2, and Breast Cancer (NCI; PI: Bernstein)
2005-2008	ATM Mutations in Breast Cancer – A Functional Approach (NCI; PI: Concannon)
2005-2009	Breast Cancer, Radiation and the ATM-Chek2 Pathway (NCI; PI: Bernstein)
2003-2005	Chek2*1100delC (DCS; PI: Olsen)

Planned WECARE Study II

Goal

To follow-up initial ATM gene-radiation interaction findings:

- Focus on long latency and youngest cases
- Increase cases → more data collection centers needed
- Maintain consortium infrastructure

Lessons Learned: Interdisciplinary Partnerships

What Worked Well

- Study Team Composition- Broad and Deep
 - Expertise in every aspect of the study
 - Prior track record and collaboration with other team members
- Working Group Communication-Constant
 - Within Group
 - Bi-monthly conference calls
 - Monthly data delivery and progress reports
 - Dedicated web-site
 - Between Group
 - Annual/ semi-annual key investigator meetings
- Internal Advisory Group- Accessible
- Support from NCI

Lessons Learned: Interdisciplinary Partnerships

What Didn't Work as Well

- Overall Communication
 - Annual meetings and e-mails barely adequate
- Committees Formed Post Hoc
 - Subcommittees
- Study Team Composition
 - Ideal mix would include junior and senior investigators
- Funding
 - Difficult to maintain infrastructure now that WECARE: ATM funding is finished